Nanobiotix has presented complete outcomes from the dose escalation and dose expansion phases of the Phase I trial of ...

Janux Therapeutics has commenced Phase Ib expansion trials with JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial.

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.

The stages of clinical trial transition include strategic initiation and planning to establish action points within the ...

Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...

Chengdu Origen and Vanotech have initiated the first subject dosing in the Phase I trial, VAN-2401, of KH658 for treating wet ...

OBI Pharma has received clearance from the US FDA for an IND application for OBI-902 to begin a Phase I/II trial for advanced ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

BioCardia has announced the enrolment of the first subject in CardiAMP HF II trial of its cell therapy for treating heart ...

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Bretzi met the primary endpoint, showing significant improvement in lung function compared with ICS/LABA medicines. Credit: Prostock-studio/Shutterstock. AstraZeneca ...